Gold prices edge higher on raised Fed rate cut hopes
Patricia Carr, the Senior Vice President and Chief Accounting Officer at Jazz Pharmaceuticals (NASDAQ:JAZZ), recently executed several stock transactions, according to a regulatory filing. On February 27, 2025, Carr sold a total of 5,586 ordinary shares, generating proceeds of approximately $805,842. The sale prices ranged from $143.295 to $144.4162 per share. The transactions occurred as Jazz’s stock trades near its 52-week high of $148.06, with the company maintaining impressive gross profit margins of 92.4% and trading at a P/E ratio of 15.5.
In addition to these sales, Carr also acquired shares through the exercise of stock options. She exercised options to acquire 4,813 shares, with prices ranging from $113.1 to $123.36 per share, totaling approximately $547,561. According to InvestingPro analysis, Jazz Pharmaceuticals appears undervalued at its current market capitalization of $8.51 billion, with 13 additional exclusive insights available to subscribers.
Additionally, Carr was granted 2,889 restricted stock units at no cost, which are set to vest over a four-year period. These transactions are part of her ongoing management of equity compensation, reflecting both sales for liquidity and acquisitions for future potential gains. The company’s management has been actively buying back shares, as revealed in InvestingPro’s comprehensive research report, which provides detailed analysis of Jazz’s financial health and growth prospects.
In other recent news, Jazz Pharmaceuticals reported its Q4 2024 earnings, surpassing analyst expectations with an earnings per share (EPS) of $6.60, compared to the forecasted $5.79. The company’s revenue for the quarter reached $1.1 billion, exceeding the anticipated $1.06 billion. Jazz Pharmaceuticals provided financial guidance for 2025, with revenue projections between $4.15 billion and $4.4 billion, indicating a 5% growth. Needham analyst Ami Fadia raised the stock target for Jazz Pharmaceuticals to $210, citing the company’s recent earnings and positive updates, including a settlement on Epidiolex extending its market exclusivity into the late 2030s.
RBC Capital Markets adjusted its price target for Jazz Pharmaceuticals to $178, maintaining an Outperform rating, while noting uncertainties in the company’s pipeline and leadership. The delay in the Phase III HERIZONGEA-01 study for Ziihera has shifted its anticipated results to the second half of the year. Jazz Pharmaceuticals’ sleep franchise and the cannabis-derived drug Epidiolex continue to show strong performance. The company also announced the FDA approval for Xyhara, a treatment for HER2 positive biliary tract cancer, marking significant progress in its product portfolio.
Despite these positive developments, Jazz Pharmaceuticals’ stock experienced a decline in after-hours trading. The company’s long-term growth strategy includes a focus on strategic investments in neuroscience, oncology, and rare diseases. Analyst feedback suggests a cautious yet optimistic view on Jazz Pharmaceuticals’ future prospects, with strategic management and commercial execution being key factors in maintaining positive ratings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.